Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Peregrine Pharmaceuticals Inc announces preclinical data shows combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression


Monday, 11 Aug 2014 08:00am EDT 

Peregrine Pharmaceuticals Inc:Says preclinical data further validating potent immune-stimulatory mechanism of its phosphatidylserine (PS)-targeting immuno-oncology platform.Results show that combination of PS-targeting antibody equivalent to bavituximab administered with an anti-PD-1 antibody displayed statistically significant tumor growth suppression.Says while also demonstrating significant increase in tumor-fighting T-cells into tumor microenvironment compared to anti-PD-1 antibody treatment alone in immune competent animal model of breast cancer.Bavituximab is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.Says these data further validate that blocking the immunosuppressive effects of PS facilitate an increase in tumor-fighting T-cells, and that the combination with PD-1 then allows for a more effective anti-tumor T-cell response. 

Company Quote

1.43
0.02 +1.42%
21 Nov 2014